Segment, Customer and Geographical Reporting (Tables)

12 Months Ended

Sep. 30, 2018

The Company’s segment information is summarized below:

Results of Operations for the Fiscal Year Ended September 30,
2018
	Optics			Innovation and Development (formerly Contract Research)			Biomedical			Total
Revenue	$	23,053,000		$	17,628,000		$	-		$	40,681,000
Gross profit		7,667,000			7,569,000			-			15,236,000
GM %		33	%		43	%		-			37	%
Operating expenses		7,003,000			7,072,000			817,000			14,892,000
(Gain) loss on sale of assets		-			-			-			-
Impairment of long-lived assets		-			-			182,000			182,000
Operating income (loss)		664,000			497,000			(999,000	)		162,000

Depreciation and amortization		1,006,000			237,000			14,000			1,257,000
Capital expenditures		2,033,000			211,000			73,000			2,317,000

Intangibles, net		390,000			162,000			203,000			755,000
Goodwill		961,000			4,939,000			-			5,900,000
Total assets	$	22,946,000		$	8,376,000		$	210,000		$	31,532,000

Results of Operations for the Fiscal Year Ended September 30,
2017
	Optics			Innovation and Development (formerly Contract Research)			Biomedical			Total
Revenue	$	19,282,000		$	18,002,000		$	-		$	37,284,000
Gross profit		6,562,000			7,336,000			-			13,898,000
GM %		34	%		41	%		-			37	%
Operating expenses		6,183,000			6,856,000			1,381,000			14,420,000
(Gain) loss on sale of assets		-			-			60,000			60,000
Impairment of long-lived assets		-			-			-			-
Operating income (loss)		379,000			480,000			(1,441,000	)		(582,000	)

Depreciation and amortization		970,000			257,000			11,000			1,238,000
Capital expenditures		575,000			338,000			69,000			982,000

Intangibles, net		467,000			196,000			324,000			987,000
Goodwill		1,001,000			4,939,000			-			5,940,000
Total assets	$	20,445,000		$	8,078,000		$	574,000		$	29,097,000

Revenue by geographic location in total and as a percentage of total revenue, for the years ended September 30, 2018 and 2017 are as follows: